This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (21)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Pilot Study

Margaret M. Hoehn

Arch Neurol. 1980;37(3):146-149.

Abstract
• Twenty-one patients with Parkinson's disease were studied because their low maintenance dosages of carbidopa-levodopa in the customary ratio of 1:10 provided less than the daily 75 mg of carbidopa believed nescessary to achievo full inhibition of extracerebral dopa decerboxylation. The dosage of carbidopa was increassd 2.5 times to between 75 and 150 mg daily, while the mean dosage of levodopa essentially was unchanged. The new carbidopa-levodopa ratio was 1:4. During 15 months, this treatment produced a moderate decrease in the severity of parkinsonism and a marked decrease in paripheral adverse reactions, without a significant increase in the central adverse effects of levodopa. It is concluded that increasing the dosage of carbidopa may be beneficial to patients with Parkinson's disease receiving less than 75 mg of carbidopa and 750 mg of levodopa daily.

Author Affiliations
From the Department of Neurology, Universityf Colorado School of Medicine, Denver.

Footnotes
Accepted for publication April 9, 1979.

Reprint requests to Box A0A035, sity of Colorado Medical Center, 4200 E Ninth Ave, Denver, CO 80262 (Dr Hoehn).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Factor Analysis of Parkinson's Impairment: An Evaluation of the Final Common Pathway
Reynolds and Montgomery
Arch Neurol 1987;44:1013-1016.
ABSTRACT